Article Contents ::
- 1 The Brand Name MIMCIPAR Has Generic Salt :: CINACALCET
- 2 MIMCIPAR Is From Company Panacea Priced :: Rs. 1265
- 3 MIMCIPAR have CINACALCET is comes under Sub class Drugs affecting Bone Metabolism of Main Class Endocrine,Steroid Hormones , Metabolic System
- 4 Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System Sub Medicine Class :: Drugs affecting Bone Metabolism
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name MIMCIPAR Has Generic Salt :: CINACALCET
MIMCIPAR Is From Company Panacea Priced :: Rs. 1265
MIMCIPAR have CINACALCET is comes under Sub class Drugs affecting Bone Metabolism of Main Class Endocrine,Steroid Hormones , Metabolic System
Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System Sub Medicine Class :: Drugs affecting Bone Metabolism
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Hyperparathyroidism, Hypercalcemia, Parathyroid carcinoma
Drug Dose ::
Adult: PO Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis >18 yr: Initially 30 mg once daily; titrate dose every 2-4 wk in steps of 30 mg as necessary to achieve intact parathyroid hormone (iPTH) levels of 150-300pg/mL. Max: 180 mg/day. Hypercalcaemia associated w/ parathyroid carcinoma >18 yr: Initially 30 mg bid; titrate dose every 2-4 wk in sequential doses of 60 mg bid, 90 mg bid, and 90 mg 3-4 times daily as needed until serum calcium levels normalise. Max: 90 mg 4 times/day.
Drug Precautions ::
Moderate-to-severe hepatic impairment, CV diseases. Not indicated for chronic kidney disease patients who are not receiving dialysis. Do not initiate Cinacalcet in hypocalcaemic patients. For secondary hyperparathyroidism, measure serum calcium and phosphorus (prior to- and within 1 wk after initiation/dose adjustment; mthly during maintenance) and iPTH (prior to- and within 1-4 wk after initiation/dosage adjustment; every 1-3 mth during maintenance). iPTH levels should drawn at least 12 hr after Cinacalcet dosing. For parathyroid carcinoma and primary parathyroidism, measure serum calcium prior-to and within 1 wk after initiation/dose adjustment; and every 2-3 mth during maintenance. Vitamin D sterols, calcium-containing phosphate binder and/or adjustment of calcium contents of dialysis fluid can be used to raise serum calcium in the event of hypocalcaemia. Reduce dose or withhold therapy if hypocalcaemia persists; may reinstate treatment at the next lowest dose after calcium levels normalised. Significant reduction in serum calcium may lower seizure threshold. Adynamic bone disease may develop if iPTH level is suppressed to < 100 pg/mL. May decrease total and free testosterone levels. Safety and efficacy not established in patients ?18 yr. Pregnancy and lactation. Drug Side Effects ::
Nausea, vomiting, diarrheoa, anorexia, dizziness, myalgia, paraesthesia, asthenia, chest pain (non-cardiac), rash, urticaria, seizure, decreased testosterone levels, hypocalcaemia, hypotension, hypertension. Potentially Fatal: Hypersensitivity reaction including angioedema.
Pregnancy category ::
Drug Mode of Action ::
Cinacalcet is a calcimimetic agent. It lowers parathyroid hormone (PTH) secretion by increasing the sensitivity of the calcium-sensing receptor of the parathyroid gland to activation by extracellular calcium. PTH reduction leads to concomitant decrease in serum calcium and phosphorus concentrations.
Drug Interactions ::
Cinacalcet is a strong CYP2D6 inhibitor and may increase serum concentrations of amitriptyline, nortriptyline and desipramine. Cinacalcet may decrease serum concentrations of tacrolimus. CYP3A4 inhibitors such as ketoconazole, erythromycin may increase plasma concentrations of Cinacalcet.